Adc Therapeutics SA logo

ADCT

Adc Therapeutics SA

$8.54

Earnings Summary

Revenue
$46.5Mn
Net Profits
$-16.66Mn
Net Profit Margins
-35.83%

Highlights

Revenue:

Adc Therapeutics SA’s revenue jumped +Inf% since last year same period to $46.5Mn in the Q1 2022. On a quarterly growth basis, Adc Therapeutics SA has generated 173.36% jump in its revenue since last 3-months.

Net Profits:

Adc Therapeutics SA’s net profit jumped 67.67% since last year same period to $-16.66Mn in the Q1 2022. On a quarterly growth basis, Adc Therapeutics SA has generated 51.54% jump in its net profits since last 3-months.

Net Profit Margins:

Adc Therapeutics SA’s net profit margin jumped NaN% since last year same period to -35.83% in the Q1 2022. On a quarterly growth basis, Adc Therapeutics SA has generated 82.27% jump in its net profit margins since last 3-months.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the Adc Therapeutics SA post its latest quarter earnings

EPS Estimate Current Quarter
-0.7
EPS Estimate Current Year
-0.7

Highlights

EPS Estimate Current Quarter:

Adc Therapeutics SA’s earning per share (EPS) estimates for the current quarter stand at -0.7 - a 18.6% jump from last quarter’s estimates.

EPS Estimate Current Year:

Adc Therapeutics SA’s earning per share (EPS) estimates for the current year stand at -0.7.

Key Ratios

Key ratios of the Adc Therapeutics SA post its Q1 2022 earnings

Earning Per Share (EPS)
-0.22
Return on Assets (ROA)
-0.29
Return on Equity (ROE)
-1.04
Dividend Per Share (DPS)
0

Highlights

Earning Per Share (EPS):

Adc Therapeutics SA’s earning per share (EPS) jumped 67.16% since last year same period to -0.22 in the Q1 2022. This indicates that the Adc Therapeutics SA has generated 67.16% annual rate of jump in its earning per share (EPS) in the last 4 quarters.

Return on Assets (ROA):

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Adc Therapeutics SA’s return on assets (ROA) stands at -0.29.

Earning Per Share (EPS):

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Adc Therapeutics SA’s return on equity (ROE) stands at -1.04.

Dividend Per Share (DPS):

Adc Therapeutics SA declared 0 dividend per share during the earnings announcement for Q1 2022.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %
2021-09-30
-0.92
-0.93
-1.09%
2021-06-30
-0.86
-0.95
-10.47%

Company Information

ADC Therapeutics SA is a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of potent and targeted antibody drug conjugates (ADCs) for patients with hematological malignancies and solid tumors. The Company has created a deep clinical pipeline by combining its decades of experience and strategic target selection with proprietary next-generation pyrrolobenzodiazepine (PBD) technology. The Company's Biologics License Application for its lead product candidate, loncastuximab tesirine (Lonca, formerly ADCT-402) for the treatment of relapsed or refractory diffuse large B-cell lymphoma was given priority review status by the U.S. Food and Drug Administration and a Prescription Drug User Fee Act (PDUFA) target date of May 21, 2021. The Company's second lead product candidate, camidanlumab tesirine (Cami, formerly ADCT-301), is being evaluated in a 117-patient pivotal Phase 2 clinical trial for the treatment of relapsed or refractory Hodgkin lymphoma.

Organisation
Adc Therapeutics SA
Headquarters
Biopole, Epalinges, Switzerland, 1066
Employees
208
Industry
Health Technology